hit counter
BioXcel Therapeutics, Inc. (BTAI) Stock News Sentiment & Price - Sentifly
BTAI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



BioXcel Therapeutics, Inc. (BTAI)

USA
Biotechnology
NASDAQ
BTAI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BTAI Latest news
Seeking Alpha
Positive
BioXcel Therapeutics: Ready To Enter The Depression Therapeutic Field
2021-10-24 03:48

The company intends to expand the indication of BXCL501 to treat anxious depression.

The Motley Fool
Positive
This High-Risk, High-Reward Stock Might Double Your Money
2021-10-20 10:00

After a difficult year, shares of this biotech could bounce back big.

GlobeNewsWire
Neutral
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
2021-10-18 07:00

Initial findings from Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA met efficacy threshold to support expansion of existing cohort of de novo and treatment-emergent Small-Cell Neuroendocrine Prostate Cancer (SCNC)

The Motley Fool
Negative
Why BioXcel Therapeutics Stock Is Sinking Today
2021-10-14 11:39

The company's chief commercial officer resigned.

GlobeNewsWire
Neutral
BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day
2021-09-23 07:00

Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders

GlobeNewsWire
Neutral
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
2021-09-15 18:06

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma

GlobeNewsWire
Neutral
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
2021-09-12 18:05

NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology (ESMO) Congress, which will take place virtually from September 16-21, 2021.

GlobeNewsWire
Neutral
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
2021-09-09 07:00

Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET

Seeking Alpha
Positive
BioXcel: Recent Selloff Offers A Very Good Opportunity To Entry At A Discount Price
2021-08-18 14:32

Any investor who looks at the stock price chart during this year 2021 will be shadowed by the sharp drop that it presents.

Seeking Alpha
Neutral
BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript
2021-08-10 12:19

BioXcel Therapeutics, Inc. (BTAI) CEO Dr. Vimal Mehta on Q2 2021 Results - Earnings Call Transcript

Loading more news...